Case No. 3:25-cv-04108-MMC

- 1. I am the Chief Executive Officer of CureIS Healthcare Inc. ("CureIS"). I have personal knowledge of the matters set forth in this Declaration, and if called as a witness I would testify competently to those matters.
- 2. I previously submitted a declaration in support of CureIS's May 12, 2025 Administrative Motion for leave to File Under Seal Portions of its Complaint. The Court granted CureIS's sealing request on May 13, 2025. (Dkt. 5.)
- 3. I also submitted a declaration in support of CureIS's July 14, 2025 Administrative Motion for leave to File Under Seal Portions of its Amended Complaint. (Dkt. 38.)
- 4. I make this declaration in support of CureIS's Administrative Motion for Leave to File Under Seal Portions of its Opposition to Epic's Motion to Partially Unseal CureIS's Complaint (the "Administrative Motion") and my accompanying Declaration in Opposition to Epic's Motion to Partially Unseal CureIS's Complaint. ("Sawotin Decl.").
- 5. CureIS's Opposition ("Opposition") and my accompanying declaration, proposed to be filed partially under seal, contain CureIS's and CureIS's customers' highly confidential information, including confidential customer identities, and information from confidential agreements and contractual negotiations. The following limited portions of CureIS's Opposition and the Sawotin Declaration and highlighted in the unredacted Opposition and Sawotin Declaration filed as Exhibits A and B to this Declaration, contain CureIS's and CureIS's customers' confidential information, which would likely harm CureIS's competitive standing and the competitive standing of its customers if publicly disclosed:

Opposition Selections	Reasons for Sealing (Highlighted Portions Only)	
D _m 2.0, 0.16 17	Non-public and commercially sensitive information	
Pp. 3:9; 9:16-17	regarding CureIS's customer relationships and confidential customer contracts	
Sawotin Declaration	customer contracts	
Paragraphs	Reasons for Sealing (Highlighted Portions Only)	
7	Non-public and commercially sensitive information	
	regarding CureIS's customer relationships and confidential	
	customer contracts	

1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
	ı	

- 6. Public disclosure of this information could significantly harm CureIS competitively in addition to the competitive standing of CureIS's current and former customers, as well as violate CureIS's contractual obligations to its customers. CureIS requires its employees to undergo training on maintaining the confidentiality of CureIS's proprietary information and the confidential information of CureIS's customers. In addition, CureIS enters into Non-Disclosure Agreements ("NDA") with third parties before sharing product development and implementation proposals, commencing contract negotiation discussions, or allowing access to its proprietary product infrastructure.
- 7. Attached to this Declaration as Exhibit A is an unredacted version of CureIS's Opposition
- 8. Attached to this Declaration as **Exhibit B** is an unredacted version of the Sawotin Declaration in support of CureIS's Opposition.

I declare under penalty of perjury under the laws of the State of California and the United States of America that the foregoing is true and correct, and that this declaration was executed in Ketchikan, Alaska, on July 18, 2025.

Christopher Sawotin, CEO of CureIS Healthcare Inc.

26

27 28